Dror Bashan Net Worth

The estimated Net Worth of Dror Bashan is at least $737 Thousand dollars as of 19 October 2023. Mr Bashan owns over 64,516 units of Protalix BioTherapeutics stock worth over $137,817 and over the last 5 years he sold PLX stock worth over $0. In addition, he makes $599,387 as Pres and CEO & Director at Protalix BioTherapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Bashan PLX stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Protalix BioTherapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 64,516 units of PLX stock worth $90,322 on 19 October 2023.

The largest trade he's ever made was buying 68,000 units of Protalix BioTherapeutics stock on 11 April 2022 worth over $102,000. On average, Mr trades about 16,565 units every 70 days since 2019. As of 19 October 2023 he still owns at least 132,516 units of Protalix BioTherapeutics stock.

You can see the complete history of Mr Bashan stock trades at the bottom of the page.

Mr. Dror Bashan biography

Dror Bashan is the Pres, CEO & Director at Protalix BioTherapeutics.

What is the salary of Mr Bashan?

As the Pres and CEO & Director of Protalix BioTherapeutics, the total compensation of Mr Bashan at Protalix BioTherapeutics is $599,387. There are 1 executives at Protalix BioTherapeutics getting paid more, with Dr. Einat Brill-Almon having the highest compensation of $665,703.

How old is Mr Bashan?

Mr Bashan is 54, he's been the Pres and CEO & Director of Protalix BioTherapeutics since . There are 10 older and 3 younger executives at Protalix BioTherapeutics. The oldest executive at Protalix BioTherapeutics Inc. is Aharon Schwartz, 75, who is the Independent Director.

What's Mr Bashan's mailing address?

Dror's mailing address filed with the SEC is C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, L3, 2161401.

Insiders trading at Protalix BioTherapeutics

Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber, and Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.

What does Protalix BioTherapeutics do?

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase

Complete history of Mr Bashan stock trades at Protalix BioTherapeutics

Protalix BioTherapeutics executives and stock owners

Protalix BioTherapeutics executives and other stock owners filed with the SEC include:

• Dr. Einat Brill-Almon,
  Sr. VP & Chief Devel. Officer
• Dror Bashan,
  Pres, CEO & Director
• Einat Almon,
  Senior Vice President, Chief Development Officer
• Eyal Rubin M.B.A.,
  Sr. VP, CFO, Treasurer & Corp. Sec.
• Marcy Nanus,
  Investor Contact
• Aharon Schwartz,
  Independent Director
• David Granot,
  Independent Director
• Amos Bar-Shalev,
  Independent Director
• Gwen Melincoff,
  Director
• Pol Boudes,
  Director
• Yael Hayon,
  Vice President - Research & Development
• Yaron Naos,
  Senior Vice President - Operations
• Eyal Rubin,
  Chief Financial Officer, Senior Vice President
• Dror Bashan,
  President, Chief Executive Officer, Director
• Zeev Bronfeld,
  Chairman of the Board
• Dafna Shelly M.Sc., MBA,
  VP of HR
• Yaron Naos,
  Sr. VP of Operations
• Capital Management Lp Camber,
  10% owner
• Yoseph Shaaltiel,
  Executive VP, R&D
• Tzvi Palash,
  Chief Operating Officer
• Moshe Manor,
  President & CEO
• Yossi Maimon,
  VP, Chief Financial Officer
• Sandra Leigh Lauterbach,
  VP, Sales & Commercial Affairs
• David Aviezer,
  President & CEO
• Ltd Bio Cell,
  10% owner
• Shlomo Yanai,
  Director
• Alfred Akirov,
  Director
• Eli Hurvitz,
  Director
• Roger D. Kornberg,
  Director
• Phillip Md Et Al Frost Gamm...,
  
• Iftah Katz,
  VP of Operations
• Pharma Technologies Ltd.Ore...,
  
• Eliot Forster,
  Director
• Zvi Shmuel Ben,